Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

US drug maker <keyword id="44612" type="General" weightage="20" keywordseo="pfizer" source="Orion">Pfizer</keyword>'s Covid-19 vaccine is likely to get authorization for providing vaccines to children aged between 5 to 12 by October, according to Scott Gottlieb, former head of the Food and Drug Administration (FDA). Currently of the three Covid-19 vaccines used in the US, only the Pfizer-BioNTech vaccine has been granted the emergency use authorisation for children aged 12 and older. Pfizer along with Moderna and Johnson and Johnson are conducting clinical trials to evaluate the safety and efficacy of the vaccines in children under 12. Results of the Pfizer vaccine for children are expected in September. "Pfizer will be in a position to file data with the FDA at some point next month, and then submit its application to expand its emergency use authorisation for its vaccine in children 5 years and older as early as October," Gottlieb was quoted as saying in an interview on CBS News on Sunday. "The agency (FDA) will be in a position to make an authorisation, I believe, at some point, late fall, probably early winter. "And probably they're going to base their decision on what the circumstances around the country are, and what the urgency is to get a vaccine for kids," Gottlieb, who is also a member of Pfizer's board of directors, told CBC News. Pfizer has also been conducting clinical trials of its Covid-19 shot in children ages 2 and older. The results will be available in November. If the FDA authorises Pfizer's vaccine in kids between the ages of 5 and 11 in November or early December, "that, again, puts you on a timeframe that you could start rolling out these vaccinations before the end of the year", Gottlieb noted. Vaccinating younger children against Covid would be crucial as the highly contagious Delta variant is driving cases, particularly among the children. According to Gottlieb, there are roughly 300 kids being hospitalised each day with Covid-19, and infection rates among children have spiked with schools reopening. The two "best things" schools can do, Gottlieb said, is testing students twice a week and keeping them in geographic or social pods to cut down on intermingling among the full student body. Gottlieb also advocated for students to wear face masks and schools to improve ventilation, as well as vaccinated those who are currently eligible. SEE ALSO <a href="https://www.businessinsider.in/science/health/news/mukesh-ambanis-reliance-life-sciences-gets-approval-to-conduct-trials-for-its-covid-19-vaccine/articleshow/85677741.cms">Mukesh Ambani-owned Reliance Life Sciences' COVID-19 vaccine — here's all we know so far</a> <a href="https://www.businessinsider.in/business/auto/news/tata-motors-is-the-casualty-of-jlr-struggling-due-to-the-global-chip-shortage-and-a-lacklustre-ev-vision/articleshow/85652897.cms">Tata Motors is paying the price because Jaguar Land Rover has been slow in the EV race</a>

Pfizer's COVID-19 vaccine may be authorised for kids aged 5-12 by October, says company's board member

<keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword>'s drug regulator may soon grant restricted emergency use authorisation for <keyword id="4912868" type="PERSON" weightage="20" keywordseo="moderna">Moderna</keyword>'s <keyword id="8904563" type="UNKNOWN" weightage="20" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword>, official sources said on Tuesday. In a separate communication, Moderna has informed that the US has agreed to donate a certain number of doses of its COVID-19 vaccine through COVAX to the Government of India for use here and has sought approval from the Central Drugs Standard Control Organisation (CDSCO), while <keyword id="6357157" type="COMPANY" weightage="20" keywordseo="cipla">Cipla</keyword>, on behalf of the US pharma major, has requested for import and marketing authorization of these jabs. According to the sources, an approval is likely anytime as the CDSCO is in favour of granting permission to Cipla for import of Moderna's COVID-19 vaccine for restricted emergency use in India considering the pandemic situation in the country and in public interest. Cipla filed an application on Monday seeking permission for import of Moderna's COVID-19 vaccine referring to DCGI notices dated April 15 and June 1 as per which if the vaccine is approved by the <keyword id="44669" type="COMPANY" weightage="20" keywordseo="USFDA">USFDA</keyword> for EUA, the vaccine can be granted marketing authorisation without bridging trial and assessment of safety data of first 100 beneficiaries of vaccines shall be submitted before rolling out in immunization programme. Also, the requirement of testing of every batch by the Central Drugs Laboratory (CDL), Kasauli can be exempted if the batch/lot is released by the CDL of country of origin. However, summary lot protocol review and scrutiny of documents shall be undertaken by the laboratory for batch release as per standard procedures, Cipla said referring to the DCGI's new revised rules. Moderna through a separate communication has informed that the <keyword id="48028" type="COMPANY" weightage="20" keywordseo="US-government">US Government</keyword> has agreed to donate a certain number of doses of the <keyword id="9708420" type="UNKNOWN" weightage="20" keywordseo="moderna-covid-19-vaccine">Moderna COVID-19 Vaccine</keyword>, mRNA-1273, through COVAX to the Government of India for use in India and has submitted the dossiers through e-mail. "This correspondence is to request the CDSCO to open a file for approval of these urgently needed vaccines," Moderna said. In a bid to expedite the roll out of vaccines, the DCGI on June 1 decided to waive off testing of batches at CDL for foreign-manufactured vaccines that have been approved by international drug regulators such as the US FDA, the UK's MHRA or the WHO. The Centre had in April issued detailed guidelines and proactively eased entry of foreign made COVID-19 vaccines approved by the US FDA, EMA, UK's MHRA and Japan's PMDA, and WHO's Emergency Use Listing into India. According to the guidelines, these vaccines will not need to undergo prior bridging trials. The provision was further amended to waive off the trial requirement altogether for the well-established vaccines manufactured in other countries.

COVID-19: India's drug regulator may soon give restricted emergency use authorisation to American vaccine Moderna

<ul><li>According to the government, over 30 vaccine candidates are being developed in India. </li><li>Serum Institute of India has entered phase II/III trials and is leading the vaccine development race in the country. </li><li>Whereas, both Bharat Biotech and Zydus Cadila are conducting <a href="https://health.economictimes.indiatimes.com/news/industry/human-clinical-trials-for-covid-19-vaccine-initiated-in-india-icmr/76969682">phase I/II human</a> trials right now. </li></ul>As India records over 1 million COVID-19 deaths, scientists in India are racing against time to develop an effective vaccine. There are 191 COVID-19 vaccine developments in the works around the world right now, and 41 of them are under clinical evaluation, according to the World Health Organisation. According to the Indian government, over 30 vaccine candidates are being developed in India. Three of them are in the advanced stages of the trial, while four are in the pre-clinical development stage. Serum Institute of India is leading the vaccine development race in the country. SII and the Indian Council of Medical Research (ICMR) are jointly conducting phase II/III trials of Oxford’s <keyword id="8624004" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword> in India. Here are the latest developments on COVID-19 vaccines in India: No major adverse side-effects reported so far in vaccine trial at PGI Chandigarh The late phase trials of the Oxford-AstraZeneca vaccine, known as Covishield in India, are well underway at the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, the institute said on Thursday The officials at the premier institute told IANS that no adverse side-effects among the volunteers have been observed so far. "Very few people developed fever or body ache post vaccine administration. It is expected and very normal after the vaccine dose is given. Nothing to get alarmed about," an official informed. The institute is listed as one of the 17 trial sites for conducting the second and third phases of human clinical trials of the Coveshield vaccine. The officials added that 53 participants in the trials have already completed seven days of post vaccination period without developing any major side-effects. They also informed that the institute has screened 97 volunteers till date and 65 of them have already been administered the first dose of the vaccine. Indian-origin researchers use bovine adenovirus to develop coronavirus vaccine Oct 8 (IANS) A team of Indian-origin researchers in the US is working to develop a unique Covid-19 vaccine that uses a bovine adenovirus that will protect all segments of the population, especially older adults. Bovine Adenovirus, also known as BAdV, is a member of the Adenoviridae family that causes disease in cattle. "Adenoviral vectors have emerged as a promising gene-delivery platform for a variety of therapeutic and vaccine purposes during the last two decades," said study author Suresh Kuchipudi from Penn State University in the US Moderna to apply for real-time reviews for its COVID-19 virus in Europe: Reuters US pharma giant Moderna said it will apply real-time reviews in Europe. It is in talks with European countries and is also planning to get approval from U.S. Food and Drug Administration. Real-time reviews will allow researchers to give feedbacks without waiting for studies to conclude, reported <a href="https://www.reuters.com/article/us-health-coronavirus-moderna/moderna-to-apply-for-eus-rolling-approval-for-covid-19-vaccine-idUSKBN26T21A" data-type="tilCustomLink">Reuters. </a> Government to map out cold chain storage facilities for COVID-19 vaccine delivery With the likelihood of a vaccine against coronavirus being available within months, the government has begun a massive exercise to map out cold chain storage facilities to ensure the vaccine is delivered quickly across the country. A national expert group is talking to public and private sector entities in the pharmaceutical sector, food processing industry and agro businesses as well as food delivery start-ups such as Swiggy and Zomato to identify cold storages or fridges at the taluka level that can stock and distribute the vaccine, sources with direct knowledge of the discussions said. India's drug controller reject Dr. Reddy's proposal to test Russian coronavirus vaccine India's drug controller has rejected Dr. Reddy's proposal to test Russian coronavirus vaccine in a large study stating early-age study to be small. An expert panel of Central Drugs Standard Control Organisation has asked Dr Reddy's to first conduct small study. Previously, CDSCO asked Dr Reddy's Laboratories to submit a revised protocol for conducting both phase 2 and phase 3 human clinical trials for the Russian vaccine against COVID-19, Sputnik V, in India, sources said Monday.The Hyderabad-based pharmaceutical company had applied to the Drugs Controller General of India (DCGI) late last week, seeking permission to conduct phase-3 human clinical trials of the Russian vaccine. India plans procure 400-500 million doses of vaccine for 25 crore people by 2021 Union Health Minister Harsh Vardhan said on Sunday that the Centre is working on plans to procure 400-500 million doses of Covid-19 vaccine, which will be administered to up to 25 crore people by July 2021. He also indicated that the frontline workers and those having underlying health conditions are in the top priority list of the government for vaccine administration, saying that his ministry is currently preparing a format in which states will submit lists of priority population groups to receive the vaccine, especially health workers engaged in the management of Covid-19. In India, three potential COVID-19 vaccines are under advanced clinical trials According to <a href="https://vaccine.icmr.org.in/covid-19-vaccine">ICMR</a>, there are three potential COVID-19 vaccines under human trials — Bharat Biotech’s COVAXIN, Oxford’s Covishield, and Zydus Cadila’s ZyCoV-D. Serum Institute of India has already begun phase III trials of Oxford’s vaccine candidate at 17 sites across the country. Whereas, both Bharat Biotech and Zydus Cadila are conducting <a href="https://health.economictimes.indiatimes.com/news/industry/human-clinical-trials-for-covid-19-vaccine-initiated-in-india-icmr/76969682">phase I/II human</a> trials right now. India likely to approve potential COVID-19 vaccine with 50% efficiency The Indian drug regulator, Central Drugs Standard Control Organization, earlier this week, said it is planning<a href="https://www.livemint.com/news/india/india-may-approve-covid-19-vaccines-that-show-50-efficacy-in-clinical-trials-11600764175238.html"> </a>on approving the COVID-19 vaccine that can protect 50% of the participants in phase III human trials. “To ensure that a widely deployed COVID-19 vaccine is effective, the primary efficacy endpoint point estimate for a placebo-controlled efficacy trial should be at least 50%," the Central Drugs Standard Control Organization (CDSCO) The Health Ministry also launched a <a href="https://vaccine.icmr.org.in/">portal </a> on September 29 that will provide important information on vaccine development, ongoing clinical trials and progress made - both locally and globally. Previously, World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus has <a href="https://www.livemint.com/news/india/who-chief-lauds-pm-modi-for-his-commitment-in-fight-against-covid-19-pandemic-11601181436330.html">lauded </a>Prime Minister Narendra Modi's assurance that India will use its vaccine production capacity in helping nations fight COVID-19. WHO chief said that the pandemic can be defeated only by mobilising resources for common good. The Indian government is optimistic about getting a COVID-19 vaccine by the start of 2021. Moreover, the Ministry of Health and information <a href="https://www.ndtv.com/india-news/dont-agree-with-rs-80-000-crore-figure-for-covid-vaccine-distribution-centre-2302956">believe </a>they’ve sufficient funds to distribute COVID-19 vaccines in the country. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/policy/economy/news/manufacturing-in-india-improved-for-a-second-straight-month-sees-fastest-pace-of-growth-in-over-8-years/articleshow/78422225.cms">Manufacturing in India improved for a second straight month — sees fastest pace of growth in over 8 years</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/reliance-has-bagged-nearly-half-of-all-private-equity-investments-in-india-this-year-and-that-doesnt-include-the-10-billion-from-facebook-and-google/articleshow/78422299.cms">Reliance has bagged nearly half of all private equity investments in India this year – and that doesn’t include the $10 billion from Facebook and Google</a>

India COVID-19 vaccine updates — Oxford's potential coronavirus vaccine reports no side affect so far in vaccine trial at PGI Chandigarh

<ul><li>The final results of Pfizer and BioNTech’s COVID-19 vaccine show that it's 95% effective. </li><li>The only significant side effect, with a frequency of over 2%, was fatigue. </li><li>The company plans to file for Emergency Use Authorisation (EUA) with the US’ Food and Drug Administration (FDA) within the next few days. </li></ul>The COVID-19 vaccine being developed by Pfizer and BioNtech is 95% effective according to its <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine">final analysis</a>. Even in adults over the age of 65 years, the efficacy was observed at 94%. “No serious safety concerns were observed in the COVID-19 vaccine trial,” said the <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine">press note</a> issued by both companies. The phase 3 study only showed mild to moderate side effects that cleared up quickly. “The only significant side effect than that 2% in frequency was fatigue at 3.7%,” the study highlighted. How does the vaccine work? With a 95% efficacy rate, those who get the vaccine will be protected within 28 days of the first dose — and there is only a two-dose schedule. This is far more effective than the threshold laid out by the White House coronavirus advisor Anthony Fauci, who has previously stated that a vaccine that is 50% to 60% effective would be acceptable. When will the vaccine be able for the public? Now that the vaccine is ready for market as soon as it gets the required permissions, Pfizer and BioNTech plan to make up to 50 million doses before the end of the year and another 1.3 billion in 2021. According to the company, the vaccine’s efficacy is consistent across different ages, races and ethnicities. In light of the success, Pfizer plans to file for Emergency Use Authorisation (EUA) for the vaccine with the US Food and Drug Administration (FDA) within the next few days. It claims it has met all the safety data milestones required by the authorities. Why India shouldn’t rejoice just yet A year since the first COVID-19 case was detected, the success of a possible vaccine provides a ray of hope after the last seven grueling months of the pandemic. However, the Pfizer vaccine may not be suited for use in India since it requires storage at minus 70 degrees Celsius. According to the Director of the All India Institute of Medical Sciences (AIIMS) <a href="https://www.businessinsider.in/science/health/news/indian-covid-vaccines-can-survive-in-warmer-temperatures-pfizers-says-aiims-director/articleshow/79172255.cms">Randeep Guleria</a>, the Pfizer vaccine’s requirement of a lower storage temperature is something that India’s cold storage infrastructure may not be able to support for the population of 1.3 billion. However, Pfizer believes its expertise and existing cold-chain infrastructure will be enough to distribute the vaccine around the world in specially designed and temperature controlled thermal shippers that use dry ice. SEE ALSO: <a href="https://www.businessinsider.in/finance/banks/news/lakshmi-vilas-bank-customers-have-withdrawn-10000-crore-since-rbis-moratorium-was-announced-last-night/articleshow/79281857.cms">Lakshmi Vilas Bank customers have withdrawn ₹10,000 crore since RBI's moratorium was announced last night</a> <a href="https://www.businessinsider.in/careers/news/capgemini-hr-head-explains-why-the-french-it-major-is-going-crazy-hiring-in-india-and-around-the-world/articleshow/79277396.cms">EXCLUSIVE: Capgemini HR head explains why the French IT major is going crazy hiring in India and around the world</a> <a href="https://www.businessinsider.in/business/news/indiamart-and-justdial-in-legal-battle-over-copyright-violations/articleshow/79275178.cms">IndiaMart and JD Mart gear up for a legal battle over copyright infringement — even as Justdial calls IndiaMart’s allegations ‘baseless’</a>

Pfizer's new COVID-19 vaccine is 95% effective and the only severe side-effect to worry about is fatigue, according to the final results

Indian vaccines offer lot of hope, due to various factors including a good safety signal, display of immunogenicity and capability of using the current storage infrastructure, said AIIMS Director Randeep Guleria in an exclusive interview with IANS. Recently, drug company <keyword id="44612" type="CITY" weightage="20" keywordseo="Pfizer">Pfizer</keyword> announced that its vaccine candidate for Covid-19 is more than 90 per cent effective at preventing infection. This was welcomed as a major step in the fight against the virus, which has unleashed havoc on the global economy. Guleria added that the Indian Covid-19 vaccine has a huge advantage over the Pfizer vaccine, which is required to be kept at a much lower temperature, and hence, cold storage for other vaccines can be used for the Indian vaccine too. Q: We have not seen any major issue with Indian vaccines at the trials stage, are you satisfied with progress made so far? A: Indian vaccines have a lot of hope and there are two or three reasons for that, one is that their safety signal is very good and immunogenicity is also being shown, and one is now looking at the results of Phase-3 trials, which will take some time, but I am hopeful we will have good amount of data because multi-centric studies is being done. We quickly will be able to generate some interim analysis to show in Phase-3 trials this vaccine can give good efficacy. Q: Drug company Pfizer announced that its vaccine candidate for Covid-19 is more than 90 per cent effective at preventing infection. Are Indian vaccines on a better footing than Pfizer? A: What Pfizer has got is something very encouraging for other vaccines researchers also, because that shows there is a potential of good immunity by the vaccines. Therefore, other vaccines should also do well. Therefore, it is a big news for all vaccine developers. We can hope for a 90 per cent efficacy. The advantage for the Indian vaccine is that it is required to be kept at a much lower temperature. The Pfizer vaccine currently have to be kept at minus 70 degrees Celsius, therefore it will be very difficult to vaccinate people in lower- and middle-income countries. Because having a vaccine stored and transported at minus 70 degree Celsius not only needs huge investment but also needs huge planning, because most vaccines are not kept at that low temperatures. The Indian vaccines are going to be kept at a temperature of minus 20 degrees Celsius and this is available for most vaccines. As most vaccines a have cold storage facility, these can be used for this vaccine also. Therefore, the investment is not much. If we were to use a vaccine which require storage at minus 70 degrees Celsius, then one would require whole new cold chain development. I do not see that happening in lot of countries. Q: Is 90 per cent efficacy is being aimed at by Indian companies developing vaccine against Covid-19? A: We would like to have as much efficacy as one can. The WHO says if any vaccine has more than 50 per cent efficacy, it is good enough. We would definitely like to have an efficacy of 80-90 per cent. So, let us hope that is what we are able to achieve. SEE ALSO: <a href="https://www.businessinsider.in/politics/india/news/checkout-here-bihar-assembly-election-2020-results-and-updates-online/articleshow/79142084.cms">Bihar Election Results 2020: Final tally puts NDA in the majority with 125 seats as RJD remains the single largest party</a> <a href="https://www.businessinsider.in/india/news/psu-bank-employees-wage-revision-finalised-after-three-years-of-waiting-only-a-1500-increase-in-salary-for-officers/articleshow/79166497.cms">PSU bank employees wage revision finalised after three years of waiting — only a ₹1,500 increase in salary for officers</a> <a href="https://www.businessinsider.in/tech/apps/news/instagram-down-users-complain-of-frozen-timelines-and-likes/articleshow/79146012.cms">Instagram down for nearly 24 hours— users continue to complain about frozen timelines and likes</a>

Indian COVID vaccines can survive in warmer temperatures than Pfizer's, says AIIMS Director

<ul><li>India reported 96,760 <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword> infections — the highest single-day spike any country has ever added in 24 hours. </li><li>There were 1,213 deaths reported in the last 24 hours, which is also the highest fatality reported in a single day so far. </li><li>India's deaths per day are now crossing US' which is the worst-hit by the pandemic.</li></ul>Six months since WHO declared the global pandemic, India's COVID-19 tally has now crossed the 45 lakh mark. India has added 96,760 new coronavirus infections — the highest single-day spike any country has ever added in 24 hours. There were 1,213 deaths reported in the last 24 hours, which is also the highest fatality reported in a single day so far. India on September 9 reported 1,172 deaths and on September 8 there were 1,172 deaths reported. India's fatality cases per day are now crossing US' which is the worst-hit by the pandemic. On the other hand, India also saw a 100% increase in patients recovered and discharged in the past 29 days, according to the Ministry of Health. So far, 3,471,783 people have recovered from COVID-19. The overall number of global coronavirus cases has topped the 28 million mark, while the deaths have increased to over 908,000,<a href="https://coronavirus.jhu.edu/data/new-cases"> according to John Hopkins University. </a> The US accounts for the world's highest number of cases and deaths at 6,395,904 and 191,753 respectively. India currently ranks second in terms of cases at 4,465,863, while the country's death toll stood at 75,062. Brazil ranks third (4,238,446), and is followed by Russia (1,042,836), and Peru (702,776). <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">COVID-19 Infections </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">U.S </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">India </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Brazil </td></tr><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">September 10 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">38,811 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">96,760 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">40,431 </td></tr><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">September 9 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">35243 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">95,509 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">34,208 </td></tr><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">September 8 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">28, 561 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">89,706 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">17,330 </td></tr><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">September 7 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">25,325 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">75,022 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">10,188 </td></tr><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">September 6 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">31,110 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">91,723 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">14,606 </td></tr><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">September 5 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">42,092 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">90,600 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">31,199 </td></tr><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">September 4 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">52,849 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">87,115 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">45,651 </td></tr><tr><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">September 3 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">45,464 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">84,156 </td><td style="border-left:solid #000000 0.99609pt;border-right:solid #000000 0.99609pt;border-bottom:solid #000000 0.99609pt;border-top:solid #000000 0.99609pt;vertical-align:top;background-color:#ffffff;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">44,728 </td></tr></tbody></table>Source:<a href="https://www.worldometers.info/coronavirus/country/india/"> worldometers.info</a> India is not only reporting the highest number of infections over the last four weeks but is also among the few countries that have not been able to flatten its curve despite the lockdown. India is inching closer to reporting 100,000 new COVID-19 infections daily. It <a href="https://www.nytimes.com/reuters/2020/09/07/world/americas/07reuters-health-coronavirus-india-cases.html">may overtake</a> the US to become the worst-hit COVID-19 nation, experts warn. This comes as the Indian Council of Medical Research (ICMR) published the results of part two of the first national population-based serosurvey to check the transmission of COVID-19 in the country. The findings of the survey, conducted between May 11 and June 4 in 21 states, indicated that 0.73% of adults in India were exposed to Covid-19 infection, amounting to 6.4 million infections in total by early May. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/astrazeneca-says-its-coronavirus-vaccine-could-still-be-available-this-year-after-it-paused-a-crucial-trial-following-an-unexpected-illness-in-a-participant/articleshow/78042334.cms">AstraZeneca says its coronavirus vaccine could still be available this year, after it paused a crucial trial following an unexpected illness in a participant</a>

India reports 96,760 new coronavirus cases — the biggest single-day addition by any country since the pandemic began

<ul><li>Moderna has received an additional $472 million award from the US government's Biomedical Advanced Research and Development Authority (BARDA) ahead of the expanded Phase-3 <keyword id="122283" type="PERSON" weightage="20" keywordseo="Clinical-trial">clinical trial</keyword> of its Covid-19 vaccine candidate beginning on Monday. </li><li>An earlier award from BARDA for up to $483 million was entered into to support the scale up of the Covid-19 vaccine candidate and clinical development, originally with a smaller anticipated number of participants in the Phase-3 clinical trial.</li><li>The additional funding was needed to meet the requirements of the company's late stage clinical development of mRNA-1273, including the execution of the larger Phase 3 study in the US.</li></ul> Pharmaceutical company Moderna has received an additional $472 million award from the US government's Biomedical Advanced Research and Development Authority (BARDA) ahead of the expanded Phase-3 clinical trial of its Covid-19 vaccine candidate beginning on Monday. The expanded Phase-3 study of the company's mRNA vaccine candidate (mRNA-1273) against Covid-19 will include 30,000 participants, Moderna said on Sunday. An earlier award from BARDA for up to $483 million was entered into to support the scale up of the Covid-19 vaccine candidate and clinical development, originally with a smaller anticipated number of participants in the Phase-3 clinical trial. The additional funding was needed to meet the requirements of the company's late stage clinical development of mRNA-1273, including the execution of the larger Phase 3 study in the US. The total value of the award is now approximately $955 million, Moderna said. "We thank BARDA for this continued commitment to mRNA-1273, our vaccine candidate against Covid-19," said Moderna's Chief Executive Officer <keyword id="9649865" type="PERSON" weightage="20" keywordseo="stephane-bancel">Stephane Bancel</keyword>. "Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks." The Phase 3 COVE study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). Moderna said it remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021 from the company's internal US manufacturing site and strategic collaboration with Swiss drugmaker Lonza. In addition, Moderna recently announced a collaboration with US-based Catalent for large-scale, commercial fill-finish manufacturing of mRNA-1273 at Catalent's biologics facility in Indiana. Initial funding of $1.3 billion for Moderna to begin producing mRNA-1273 supply at-risk was secured from investors in the company's most recent public equity offering in May this year. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/coovid-vaccine-from-oxford-serum-institute-and-astrazeneca-shows-promising-immune-response/articleshow/77069321.cms">The COVID-19 vaccine from Oxford and AstraZeneca shows 'promising' results in early human trials</a> <a href="https://www.businessinsider.in/entertainment/news/dil-bechara-kissing-booth-2-and-other-movies-you-can-watch-on-netflix-amazon-prime-disneyhotstar-this-week/slidelist/77142498.cms">Dil Bechara, Kissing Booth 2 and other movies you can watch on Netflix, Amazon Prime, Disney+Hotstar this week</a> <a href="https://www.businessinsider.in/business/startups/news/work-from-home-effect-these-companies-are-shelling-out-for-employees-power-bills-internet-cost-and-more/articleshow/77139229.cms">WFH effect – These companies are paying for employees' power bills, internet cost and more</a>

Moderna gets additional $472 million from US for Covid-19 vaccine trial

These are the coronavirus vaccines under human trials right now

<ul><li>Moderna said on Tuesday (July 14) that it would enter the final stage of human trials for its COVID-19 vaccine on July 27 and will run at least until October.</li><li>In the Phase 3 trial, Moderna will have 30,000 participants in the US, where 50% of those will be given the vaccine at 100mg dose, and the other half will receive a placebo.</li><li>The trials were earlier scheduled to begin on July 9 but got delayed due to changes in the study plan.</li></ul>The US-based biotech firm Moderna said on Tuesday (July 14) that it would enter the final stage of human trials for its COVID-19 vaccine on July 27,<a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-publication-new-england-journal-medicine"> after the vaccine showed promising results</a>. According to reports, the Phase 3 trial Moderna will have 30,000 participants in the US, where 50% of those will be given the vaccine at 100mg dose, and the other half will receive a placebo. The coronavirus has infected more than 13 million people and killed over 581 thousand all over the world. The trials were earlier scheduled to begin on July 9 but got delayed due to changes in the study plan, according to investigators at the<a href="https://www.outlookindia.com/newsscroll/moderna-phase-3-covid19-vaccine-trial-could-still-begin-in-july/1884697"> University of Illinois at Chicago</a>. According to the US clinicaltrials.gov, the study should run until October 27 before deciding if the vaccine can still be considered a success. This came after the first stage of Moderna’s vaccine trial showed that all the first 45 participants developed antibodies to fight the virus. The <keyword id="9253744" type="UNKNOWN" weightage="20" keywordseo="Moderna-vaccine">Moderna vaccine</keyword> uses genetic material in the form of <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-publication-new-england-journal-medicine">Ribonucleic acid </a>(RNA) to help the body produce antibodies that protect against Covid-19. No vaccines based on this platform have previously received regulatory approval. This technology bypasses the need to manufacture viral proteins in the lab and helps to ramp up mass production. Moderna is working with Operation Warp Speed (OWS) and the NIH, including NIAID’s COVID-19 Prevention Trials Network (COVPN), to conduct the Phase 3 of the study. It said it aims to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, starting in 2021. Top players running for COVID vaccine There are at least 21 vaccines currently under key trials, according to the World Health Organisation (WHO). Among which the Gilead Sciences, Oxford University’s researchers and American biotech company China’s SinoVac are top players in the race of Covid-19 vaccine. China’s SinoVac is in Phase 2, while the Russian researchers have completed clinical trials on a vaccine and said it would be discharged soon. The US-based Gilead Sciences antiviral Remdesivir earlier showed that it reduces the risk of death in severely ill COVID-19 patients, but warned that rigorous clinical trials would be needed to confirm the benefit. The University of Oxford also announced last week that the advance human trial of the vaccine would involve up to 10,260 volunteers across the UK. But, according to analyst reports due to a decline in infection rate, the team at Oxford University developing a Covid-19 vaccine believe that the chances of the trial yielding “no result” is now 50%. And other Covid-19 vaccine’s by BioNTech SE and Pfizer Inc’s are expected to be ready by the end of 2020, the Wall Street Journal reported, citing the German biotech firm’s chief executive officer. SEE ALSO: <a href="https://www.businessinsider.in/international/news/trump-administration-drops-plan-to-deport-foreign-students-taking-online-only-classes-amid-coronavirus-pandemic/articleshow/76971349.cms" data-type="tilCustomLink">Trump administration drops plan to deport foreign students taking online-only classes amid coronavirus pandemic</a> <a href="https://www.businessinsider.in/science/health/news/russia-claims-worlds-first-covid-19-vaccine-after-successful-clinical-trials/articleshow/76933773.cms" data-type="tilCustomLink">Russia claims world’s first COVID-19 vaccine after successful clinical trials</a>

Moderna's COVID-19 vaccine will be in final stages of human trial starting July 27

<ul><li>“Even after India approves the coronavirus vaccine, it might not be possible to produce more than 10-20 million doses in the first year.”</li><li>The comments came from the Chairperson of Biocon in an exclusive chat with Business Insider.</li><li>Syngene, a Biocon subsidiary, is involved in accelerating a bunch of initiatives to develop a vaccine for the novel coronavirus that is spreading around the world.</li></ul>There are at least six vaccines under development in India, of the total 100 around the world including from the likes of Sanofi, Altimmune, and Pfizer. “Indian vaccine programmes will take some time before they get into the clinical trials, I think between 6 to 9 months depending on the programme. At least the ones we are working on, I don’t think they can get to clinics before 9 months,” Kiran Mazumdar Shaw, Founder and Executive Chairperson, Biocon told Business Insider. Vaccine development takes time due to the phases involved Shaw further said that vaccine development takes a lot of time because several phases are involved in it. In the first phase, a dose escalation is done to see what the ideal dose for an optimal immune response is. In the second phase, it is tested if the immune response can be done in all age groups. This is important as the first phase is conducted with young healthy volunteers who are at minimal risk. In the third phase, the vaccine is given to a larger population to ensure that the same immune response is given by everyone who is vaccinated. “One of the most important things of this phase is to check how long the immunity stays. This allows to determine how often a person will have to get revaccinated,” Shaw further noted. India will only be able to produce 10-20 million vaccines in 1 year Speaking about the production capacity, Shaw said that even after the vaccine is approved, India may not be able to produce more than 10-20 million doses in the first year, which is a negligible amount considering India’s population. See also: <a href="https://www.businessinsider.in/international/news/sanofi-one-of-the-largest-drug-makers-will-test-experimental-coronavirus-vaccine-on-humans-starting-september/articleshow/75571397.cms">Sanofi, one of the largest drug makers, will test experimental coronavirus vaccine on humans starting September</a> <a href="https://www.businessinsider.in/science/news/2-of-the-worlds-biggest-drugmakers-just-teamed-up-on-a-coronavirus-vaccine-and-theyre-aiming-to-launch-it-next-year/articleshow/75142796.cms">2 of the world's biggest drugmakers just teamed up on a coronavirus vaccine, and they're aiming to launch it next year</a>

Don’t hold your breath ⁠— Biocon founder Kiran Mazumdar Shaw says India's Covid-19 vaccine will enter clinical trials in 9 months

<ul><li>India may receive the first batch of Russia’s <keyword id="9739267" type="UNKNOWN" weightage="20" keywordseo="Sputnik-V">Sputnik V</keyword> COVID-19 vaccine is time for it to open up vaccinations for everyone above the age of 18 years.</li><li>The head of the <keyword id="1397612" type="COMPANY" weightage="20" keywordseo="Russian-Direct-Investment-Fund">Russian Direct Investment Fund</keyword> (RDIF) told Reuters that the vaccine will reach India by May 1.</li><li>The company plans to manufacture 850 million doses of Sputnik V annually in India, but a lot of that will depend on the momentum of technology transfer.</li></ul>India will receive the first batch of Russia’s Sputnik V COVID-19 vaccine by May 1. This is just in time for the country to open up vaccinations for everyone above the age of 18 years. “The first doses will be delivered on May 1,” the head of the Russian Direct Investment Fund (RDIF), Kirill Dmitriev, told <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/india-receive-first-batch-russias-covid-19-vaccine-may-1-interfax-2021-04-26/">Reuters</a>. However, he did not disclose the number of doses that will be a part of the first batch or where they will be manufactured. Sputnik V, developed by Moscow’s Gamaleya National Research Institute of Epidemiology and Microbiology, is the third vaccine after the Serum Institute of India’s (SII) Covishield and Bharat Biotech’s Covaxin to get approval from the Drug Controller General of India (DCGI). <div type="ExtQuote" text="“Following approval in India, it [Sputnik V] will be approved for use in 60 countries with a total population of over 3 billion people.”" auname="Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF) told reporters on April 14 after Sputnik V got the Drug Controller General of India’s (DCGI) approval"></div> RDIF is in charge of marketing the Sputnik V vaccine globally and has already signed agreements with six leading Indian manufacturers — Hetero Biopharma, Gland Pharma, Stelis Biopharma, Panacea Biotech, Virchow Biotech, and Shilpa Medicare. In this collaboration, RDIF hopes to manufacture over 850 million doses of the vaccine annually. By summer, it plans to hit 50 million doses a month and continue increasing output from there. A lot of this will depend on the momentum of technology transfer to allow Indian manufacturers to produce the vaccine. Virchow Biotech, for instance, is expected to complete its technology transfer between April to June, according to RDIF. Only then will it be able to commence full-scale commercial production of Sputnik V. The vaccine has also been approved by many of India’s neighbours including Sri Lanka, Myanmar and Pakistan. Russia is also lending a helping hand when it comes to Remdesivir. Pharmasyntez, a Russian company, announced that it is ready to ship up to 1 million packs of Remdesivir by the end of May, once it receives the prerequisite approval from the Russian government. <div type="Article" hostid="261" msid="82210121" title="Inside the treacherous black market for Remdesivir in India— from private hospitals to distributors" mstype="2" mssubtype="0"></div> In India, the stocks of Remdesivir have been in short supply as demand for the anti-viral drug increased alongside the surge in cases. This is despite the fact that the <keyword id="6356311" type="COMPANY" weightage="20" keywordseo="World-Health-Organisation">World Health Organisation</keyword> (WHO) has reiterated that there is no conclusive evidence to support the fact that Remdesivir is effective in the treatment of COVID-19. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/the-pace-of-infections-and-test-positivity-in-maharashtra-is-slowing-down-but-it-is-too-soon-to-celebrate/articleshow/82256149.cms">The pace of infections and test positivity in Maharashtra is slowing down — but it is too soon to celebrate</a> <a href="https://www.businessinsider.in/india/news/india-covid-19-first-wave-versus-second-wave/articleshow/82216963.cms">'We're in a much better situation' claims India's Principal Scientific Advisor as COVID-19 claims more lives than ever before</a>

You Searched For "Corona Vaccine" and got 11 results

Pfizer's COVID-19 vaccine may be authorised for kids aged 5-12 by October, says company's board member

IANS

COVID-19: India's drug regulator may soon give restricted emergency use authorisation to American vaccine Moderna

PTI

India COVID-19 vaccine updates — Oxford's potential coronavirus vaccine reports no side affect so far in vaccine trial at PGI Chandigarh

BI India Bureau

Pfizer's new COVID-19 vaccine is 95% effective and the only severe side-effect to worry about is fatigue, according to the final results

Prabhjote Gill

Indian COVID vaccines can survive in warmer temperatures than Pfizer's, says AIIMS Director

IANS

India reports 96,760 new coronavirus cases — the biggest single-day addition by any country since the pandemic began

BI India Bureau

Moderna gets additional $472 million from US for Covid-19 vaccine trial

IANS

These are the coronavirus vaccines under human trials right now

BI India Bureau

Moderna's COVID-19 vaccine will be in final stages of human trial starting July 27

Navdeep Yadav

Don’t hold your breath ⁠— Biocon founder Kiran Mazumdar Shaw says India's Covid-19 vaccine will enter clinical trials in 9 months

Rounak Jain

India will receive the first batch of Sputnik V COVID-19 vaccine by May 1 — in time for the third phase of its vaccination drive

Prabhjote Gill

Popular Keywords

Buying Guides